ALT001 clinical trials
Also written ALT001.
How each study uses ALT001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ALT001 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ALT001
- 4
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 3
yilong Wang (2) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1) · Darwin Origin (Hubei) Biopharmaceutical Co., Ltd. (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3
Studies that test ALT001.
- Jan 2027The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar TypeEarly Phase 1 · yilong Wang
- Jun 2027ALT001 in Patients With Ischemic Stroke in the Sequelae StagePhase 2 · Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.
- Oct 2027Expansion Study of ALT001 in Patients With Multiple System AtrophyEarly Phase 1 · yilong Wang
Studies
Open first, then newest update. How each study uses ALT001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- ALT001 in Patients With Ischemic Stroke in the Sequelae StageNot yet recruitingPhase 2Darwin Origin (Hubei) Biopharmaceutical Co., Ltd.NCT07841496Written as ALT001
- Expansion Study of ALT001 in Patients With Multiple System AtrophyRecruitingEarly Phase 1yilong WangNCT07476352Written as ALT001
- The Study of Safety and Preliminary Efficacy of ALT001 in Patients With MultIple System Atrophy-Cerebellar TypeRecruitingEarly Phase 1yilong WangNCT07514923Written as ALT001
- Clinical Trial on the Efficacy and Safety of ALT001 in OsteoarthritisActive, not recruitingNot applicableUnion Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07404891Written as ALT001